-
2022-502658-15-00
5
2019-09-22
Resectable Stage II-IIIB Non-small cell lung cancer
-
2024-515375-35-00
4
2019-08-26
Untreated patients with higher risk MDS and oligoblastic AML eligible
-
2023-507582-25-00
5
2019-08-02
Malignant Extracranial Germ Cell Tumours (MGCT)
-
2023-506153-38-00
5
2019-07-11
High-risk localized or locally advanced prostate cancer
-
2024-515769-32-00
5
2019-07-02
HR+/HER2- early breast cancer
-
2023-505223-31-00
4
2019-06-14
Localized ER+ breast cancer
-
2023-508681-15-00
4
2019-05-28
Adult focal (partial onset) epilepsy
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2023-505478-14-00
5
2019-05-09
Psoriatic Arthritis
-
2023-509576-42-00
5
2019-02-21
Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB
-
2022-502937-24-00
5
2019-01-02
Atopic Dermatitis
-
2022-500254-41-00
5
2018-12-13
Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamou
-
2023-505827-29-00
7
2018-10-30
Hemophilia A
-
2024-513464-26-00
5
2018-10-18
Multiple Myeloma
-
2024-514945-12-00
10
2018-09-03
locally advanced resectable adenocarcinoma of the oesophagogastric
jun
-
2024-515783-31-00
5
2018-08-24
Newly Diagnosed Multiple Myeloma
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2023-508726-10-00
5
2018-03-28
Hepatocellular Carcinoma
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-514417-34-00
5
2017-12-14
Cancer
-
2023-506399-28-00
5
2017-11-08
Crohn's Disease
-
2024-512789-32-00
5
2017-10-09
Unresectable or metastatic soft tissue sarcoma
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2024-516026-56-00
3
2017-08-17
Histologically confirmed locally advanced or metastatic solid tumor
(S